Bristol-Myers Squibb Co (BMY) Reports Solid Q4 and Full-Year 2023 Results; Plans for Future Growth [Yahoo! Finance]
Karuna Therapeutics, Inc. (KRTX)
Company Research
Source: Yahoo! Finance
GAAP EPS : Q4 at $0.87, Full-Year at $3.86, reflecting a 31% increase for the full year. Non-GAAP EPS : Q4 at $1.70, Full-Year at $7.51, indicating resilience in adjusted earnings. New Product Portfolio : Q4 revenues increased by 66% to $1.1 billion, driven by demand across the portfolio. Strategic Acquisitions : Planned acquisitions of Karuna Therapeutics and RayzeBio, and completion of Mirati Therapeutics purchase. 2024 Guidance : Expects revenue growth in low single-digits; Non-GAAP EPS range $7.10 to $7.40. Warning! GuruFocus has detected 5 Warning Signs with BMY. Bristol-Myers Squibb Co ( NYSE:BMY ) released its 8-K filing on February 2, 2024, detailing its financial results for the fourth quarter and full year of 2023. The company, a leader in the discovery, development, and marketing of drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders, has shown a strong performance in the face of industry challenges. With a significant po
Show less
Read more
Impact Snapshot
Event Time:
KRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRTX alerts
High impacting Karuna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KRTX
News
- PureTech Proposes $100 Million Capital Return [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion [Yahoo! Finance]Yahoo! Finance
- Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term [Yahoo! Finance]Yahoo! Finance
- Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor [Yahoo! Finance]Yahoo! Finance
- Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position [Yahoo! Finance]Yahoo! Finance
KRTX
Earnings
- 2/22/24 - Miss
KRTX
Sec Filings
- 3/18/24 - Form 4
- 3/18/24 - Form 4
- 3/18/24 - Form 4
- KRTX's page on the SEC website